## Yotam Bronstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10120109/publications.pdf

Version: 2024-02-01

		1478505	1588992
11	677	6	8
papers	citations	h-index	g-index
11	11	11	1710
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood, 2021, 137, 3165-3173.	1.4	539
2	Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA - Journal of the American Medical Association, 2022, 327, 341.	7.4	76
3	Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVIDâ€19 infection. Journal of Medical Virology, 2022, 94, 1241-1245.	5.0	22
4	Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. Blood Advances, 2022, 6, 148-151.	5.2	15
5	COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge. Cancer Cell, 2022, 40, 578-580.	16.8	12
6	Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. Frontiers in Oncology, 2021, 11, 646971.	2.8	7
7	REGENâ€COV antibody combination in patients with lymphoproliferative malignancies and SARSâ€CoVâ€2 infection. EJHaem, 2022, 3, 471-474.	1.0	4
8	Hemato-oncology Tourism in Israel: A Retrospective Review. JCO Global Oncology, 2020, 6, 1314-1320.	1.8	2
9	Presence of "ACKR1/DARC null―polymorphism in Arabs from Jisr az-Zarqa with benign ethnic neutropenia. Pediatric Research, 2021, , .	2.3	0
10	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. Blood, 2021, 138, 2641-2641.	1.4	0
11	The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective. Blood, 2021, 138, 4686-4686.	1.4	0